August 29, 2019


Thursday, August 29, 2019
4:00 PM – 5:00 PM EDT


Advances in Treatment of Waldenström’s Macroglobulinemia


At this patient-centered educational webinar, Dr. David MacDonald will discuss current management of Waldenström’s Macroglobulinemia in Canada and recent research advances in treatment of this rare type of non-Hodgkin lymphoma.



Dr. David MacDonald
The Ottawa Hospital
Ottawa, Ontario

Dr. Macdonald is a hematologist at The Ottawa Hospital with a focus on malignant hematology, primarily lymphoma and chronic lymphocytic leukemia (CLL). He completed a lymphoma fellowship at the BC Cancer Agency and a Clinical Trials Fellowship at the Canadian Cancer Trials Group (CCTG). He has a busy clinical practice, is actively involved in clinical trials in lymphoma, and is Director of the CORE malignant hematology clinical trials group in Ottawa. Dr. MacDonald was one of the investigators on the international Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia. He is also a member of Lymphoma Canada’s Scientific Advisory Board.